1. Scrip
  2. >>New Products

Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra

 
• By Sue Sutter

Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
Pfizer's Ixifi is the first US approval of a biosimilar wholly developed by the big pharma.

Pfizer Inc.'s Ixifi, a biosimilar version of Janssen Biotech Inc.'s tumor necrosis factor inhibitor Remicade (infliximab), received FDA approval Dec. 13, but the big pharma, which already markets an infliximab biosimilar, is not planning to compete against itself for now.

Ixifi (infliximab-qbtx) is approved for all of the eligible indications on the Remicade label: adult and pediatric Crohn's disease, ulcerative colitis, rheumatoid arthritis,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.